Coherus BioSciences (CHRS) Narrows Q4 Loss
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of ($1.47), versus ($3.68) reported last year. Revenue for the quarter came in at $6.5 million, versus $1.2 million reported last year.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
- Enovix Corporation (ENVX) PT Lowered to $5 at BofA Securities
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
